Replies to post #209163 on Innovation Pharmaceuticals Inc (IPIX)

[frrol]

Follow up reports on non-topline data are usually very comprehensive final reports, often presented at scientific conferences. You prefer they did a quick PR on OM duration and are assuming that if they don't it means the data is bad. That is poor reasoning, and pessimistic. I would rather light a candle than curse your darkness.

[Jhawker]

Fortunately what you think about what is easy or not doesn't matter. They will provide the secondary end points when they are available in the weeks come per the PR.

[DesireToLearn]

Is it safe to say, once you get OM it's difficult to eliminate it regardless of the drug?

[alwaysdreaming]

So what was reported was that 30 to 40 % of the participants did not endure severe OM, which means there is No duration time to report for those patients.

#anotherdeadhorsetobeat